100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
Previously searched by you
ASCP MLS Hematology Questions & Answers; Latest Updated Insufficient centrifugation will result in: A. A false increase in hematocrit (Hct) value B. A false decrease in Hct value C. No effect on Hct value D. All of these options, depending on the pati$10.99
Add to cart
ASCP MLS Hematology Questions & Answers; Latest Updated Insufficient centrifugation will result in: A. A false increase in hematocrit (Hct) value B. A false decrease in Hct value C. No effect on Hct value D. All of these options, depending on the pati
2 views 0 purchase
Course
ASCP MLS Hematology Questirs; Latst U
Institution
ASCP MLS Hematology Questirs; Latst U
ASCP MLS Hematology Questions & Answers; Latest Updated
Insufficient centrifugation will result in:
A. A false increase in hematocrit (Hct) value
B. A false decrease in Hct value
C. No effect on Hct value
D. All of these options, depending on the patient - Answer A. Insufficient centrifu...
A
SCP MLS Hematology
Questions & Answers; Latest
Updated
Insufficient centrifugation will result in:
A. A false increase in hematocrit (Hct) value
B. A false decrease in Hct value
C. No effect on Hct value
D. All of these options, depending on the patient - Answer A. Insufficient
centrifugation does not pack down the
,red blood cells; therefore, the Hct, which is the
volume of packed cells, will increase.
Which of the following leukemias are included in the 2008 World Health
Organization classification of myeloproliferative neoplasms?
A. Chronic myelogenous leukemia (CML)
B. Chronic neutrophilic leukemia (CNL)
C. Chronic eosinophilic leukemia (CEL)
D. All of these options are classified as
myeloproliferative neoplasms (MPN) - Answer D. The 2008 WHO classification
system includes the
following disorders under the myeloproliferative neoplasms (MPN): chronic
myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), chronic
eosinophilic leukemia (CEL), essential thrombocythemia (ET), polycythemia vera
(PV), primary (idiopathetic) myelofibrosis, hypereosinophilic syndrome, mast cell
disease, and MPNs unclassified.
In addition to morphology, cytochemistry, and immunophenotyping, the WHO
classification of myelo- and lymphoproliferative disorders is based upon which
characteristic?
A. Proteomics
B. Cytogenetic abnormalities
C. Carbohydrate-associated tumor antigen
production
,D. Cell signaling and adhesion markers - Answer B. In addition to morphology,
cytochemical stains, and
flow cytometry, the WHO classification relies heavily on chromosomal and
molecular abnormalities.
The WHO classification requires what percentage for the blast count in the blood
or bone marrow for the diagnosis of AML?
A. At least 30%
B. At least 20%
C. At least 10%
D. Any percentage - Answer B. The WHO classification of AML requires that ≥20%
of
nucleated bone marrow cells be blasts, while the FAB classification generally
requires ≥30%. WHO classifies AML into five subgroups: These are acute myeloid
leukemias with recurrent genetic disorders; acute myeloid leukemia with
multilineage dysplasia; acute myeloid leukemia and myelodysplastic syndromes,
therapy related; acute myeloid leukemia not otherwise categorized; and acute
leukemia of ambiguous lineage.
What would be the most likely designation by the WHO for the FAB AML M2 by
the French-American-British classification?
A. AML with t(15;17)
B. AML with mixed lineage
C. AML with t(8;21)
, D. AML with inv(16) - Answer C. AML with t(8;21) is classified under the category
of
AML with Recurrent Genetic Abnormalities by the WHO. This translocation occurs
in up to 15% of cases of AML and may be the most common translocation. The
AML1-ETO translocation occurs chiefly in younger patients and often in cases of
acute myeloblastic leukemia with maturation, FAB M2. The translocation involves
the fusion of the AML1 gene on chromosome 21 with the ETO gene on
chromosome 8.
What would be the most likely designation by the WHO for the FAB AML M3 by
the French-American-British classification?
A. AML with t(15;17)
B. AML with mixed lineage
C. AML with t(8;21)
D. AML with inv(16) - Answer A. AML with t(15;17) is classified under the category
of
AML with Recurrent Genetic Abnormalities by the WHO. Acute promyelocytic
leukemia (PML; known as M3 under the FAB system) is composed of abnormal
promyelocytes with heavy granulation, sometimes obscuring the nucleus, and
abundant cytoplasm. Acute promyelocytic leukemia (APL) contains a translocation
that results in the fusion of a transcription factor called PML on chromosome 15
with the alpha (α)-retinoic acid receptor gene (RARα) on chromosome 17.
Which AML cytogenetic abnormality is associated with acute myelomonocytic
leukemia with marrow eosinophilia under the WHO classification of AML with
recurrent genetic abnormalities?
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller ProfessorJaneM. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $10.99. You're not tied to anything after your purchase.
